Iva Toudjarska
Founder & CEO Zeal Therapeutics
Seminars
Wednesday 18th March 2026
Panel Discussion: How Can Novel Modalities be Used to Meet the Unmet Needs in CKD?
10:30 am
- Balancing innovation with clinical feasibility and scalable development in kidney disease
- Addressing AAV’s narrow tropism: how do we translate promise into real-world therapies?
- Exploring whether targeted delivery strategies must be disease-specific to maximize impact
- Ensuring RNAi and oligonucleotide therapies achieve durable, clinically meaningful kidney knockdown
